140 related articles for article (PubMed ID: 17004270)
21. Elucidation of Mycobacterium tuberculosis type II dehydroquinase inhibitors using a fragment elaboration strategy.
Tran AT; West NP; Britton WJ; Payne RJ
ChemMedChem; 2012 Jun; 7(6):1031-43. PubMed ID: 22461418
[TBL] [Abstract][Full Text] [Related]
22. The folding and assembly of the dodecameric type II dehydroquinases.
Price NC; Boam DJ; Kelly SM; Duncan D; Krell T; Gourley DG; Coggins JR; Virden R; Hawkins AR
Biochem J; 1999 Feb; 338 ( Pt 1)(Pt 1):195-202. PubMed ID: 9931316
[TBL] [Abstract][Full Text] [Related]
23. Tetrahydrobenzothiophene derivatives: conformationally restricted inhibitors of type II dehydroquinase.
Paz S; Tizón L; Otero JM; Llamas-Saiz AL; Fox GC; van Raaij MJ; Lamb H; Hawkins AR; Lapthorn AJ; Castedo L; González-Bello C
ChemMedChem; 2011 Feb; 6(2):266-72. PubMed ID: 21275050
[No Abstract] [Full Text] [Related]
24. Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway.
Lu H; Tonge PJ
Acc Chem Res; 2008 Jan; 41(1):11-20. PubMed ID: 18193820
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of Shikimate Kinase and Type II Dehydroquinase for Antibiotic Discovery: Structure-Based Design and Simulation Studies.
Gonzalez-Bello C
Curr Top Med Chem; 2016; 16(9):960-77. PubMed ID: 26303426
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis and evaluation of bifunctional inhibitors of type II dehydroquinase.
Toscano MD; Frederickson M; Evans DP; Coggins JR; Abell C; González-Bello C
Org Biomol Chem; 2003 Jun; 1(12):2075-83. PubMed ID: 12945898
[TBL] [Abstract][Full Text] [Related]
27. (1R,4S,5R)-3-Fluoro-1,4,5-trihydroxy-2-cyclohexene-1-carboxylic acid: the fluoro analogue of the enolate intermediate in the reaction catalyzed by type II dehydroquinases.
Frederickson M; Roszak AW; Coggins JR; Lapthorn AJ; Abell C
Org Biomol Chem; 2004 Jun; 2(11):1592-6. PubMed ID: 15162210
[TBL] [Abstract][Full Text] [Related]
28. Irreversible inhibition of type I dehydroquinase by substrates for type II dehydroquinase.
Bello CG; Harris JM; Manthey MK; Coggins JR; Abell C
Bioorg Med Chem Lett; 2000 Mar; 10(5):407-9. PubMed ID: 10743936
[TBL] [Abstract][Full Text] [Related]
29. Exploring the water-binding pocket of the type II dehydroquinase enzyme in the structure-based design of inhibitors.
Blanco B; Sedes A; Peón A; Otero JM; van Raaij MJ; Thompson P; Hawkins AR; González-Bello C
J Med Chem; 2014 Apr; 57(8):3494-510. PubMed ID: 24689821
[TBL] [Abstract][Full Text] [Related]
30. Aminoacyl-tRNA synthetases and their inhibitors as a novel family of antibiotics.
Kim S; Lee SW; Choi EC; Choi SY
Appl Microbiol Biotechnol; 2003 May; 61(4):278-88. PubMed ID: 12743756
[TBL] [Abstract][Full Text] [Related]
31. Catalytic mechanism of l,l-diaminopimelic acid with diaminopimelate epimerase by molecular docking simulations.
Brunetti L; Galeazzi R; Orena M; Bottoni A
J Mol Graph Model; 2008 Apr; 26(7):1082-90. PubMed ID: 18023379
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and evaluation of potent ene-yne inhibitors of type II dehydroquinases as tuberculosis drug leads.
Tran AT; Cergol KM; West NP; Randall EJ; Britton WJ; Bokhari SA; Ibrahim M; Lapthorn AJ; Payne RJ
ChemMedChem; 2011 Feb; 6(2):262-5. PubMed ID: 21275049
[No Abstract] [Full Text] [Related]
33. Specific chemical modification of bacterial type I dehydroquinase--opportunities for drug discovery.
González-Bello C
Future Med Chem; 2015; 7(17):2371-83. PubMed ID: 26599605
[TBL] [Abstract][Full Text] [Related]
34. Mechanistic basis of the inhibition of type II dehydroquinase by (2S)- and (2R)-2-benzyl-3-dehydroquinic acids.
Lence E; Tizón L; Otero JM; Peón A; Prazeres VF; Llamas-Saiz AL; Fox GC; van Raaij MJ; Lamb H; Hawkins AR; González-Bello C
ACS Chem Biol; 2013 Mar; 8(3):568-77. PubMed ID: 23198883
[TBL] [Abstract][Full Text] [Related]
35. Two new irreversible inhibitors of dihydrodipicolinate synthase: diethyl (E,E)-4-oxo-2,5-heptadienedioate and diethyl (E)-4-oxo-2-heptenedioate.
Turner JJ; Healy JP; Dobson RC; Gerrard JA; Hutton CA
Bioorg Med Chem Lett; 2005 Feb; 15(4):995-8. PubMed ID: 15686899
[TBL] [Abstract][Full Text] [Related]
36. 2-Trifluoroacetylthiophenes, a novel series of potent and selective class II histone deacetylase inhibitors.
Jones P; Bottomley MJ; Carfí A; Cecchetti O; Ferrigno F; Lo Surdo P; Ontoria JM; Rowley M; Scarpelli R; Schultz-Fademrecht C; Steinkühler C
Bioorg Med Chem Lett; 2008 Jun; 18(11):3456-61. PubMed ID: 18440229
[TBL] [Abstract][Full Text] [Related]
37. The folic acid biosynthesis pathway in bacteria: evaluation of potential for antibacterial drug discovery.
Bermingham A; Derrick JP
Bioessays; 2002 Jul; 24(7):637-48. PubMed ID: 12111724
[TBL] [Abstract][Full Text] [Related]
38. Structural investigation of inhibitor designs targeting 3-dehydroquinate dehydratase from the shikimate pathway of Mycobacterium tuberculosis.
Dias MV; Snee WC; Bromfield KM; Payne RJ; Palaninathan SK; Ciulli A; Howard NI; Abell C; Sacchettini JC; Blundell TL
Biochem J; 2011 Jun; 436(3):729-39. PubMed ID: 21410435
[TBL] [Abstract][Full Text] [Related]
39. Experiences with the shikimate-pathway enzymes as targets for rational drug design.
Coggins JR; Abell C; Evans LB; Frederickson M; Robinson DA; Roszak AW; Lapthorn AP
Biochem Soc Trans; 2003 Jun; 31(Pt 3):548-52. PubMed ID: 12773154
[TBL] [Abstract][Full Text] [Related]
40. The structure and mechanism of the type II dehydroquinase from Streptomyces coelicolor.
Roszak AW; Robinson DA; Krell T; Hunter IS; Fredrickson M; Abell C; Coggins JR; Lapthorn AJ
Structure; 2002 Apr; 10(4):493-503. PubMed ID: 11937054
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
